公开(公告)号：EP2786985A3

公开(公告)日：2015-01-28

申请号：EP14162609.3

申请日：2008-02-11

申请人： Metabasis Therapeutics, Inc.

发明人： Gomez-Galeno, Jorge, E. ,  Reddy, Raja, K. ,  Van Poelje, Paul, D. ,  Lemus, Robert, Huerta ,  Nguyen, Thanh, Huu ,  Grote, Matthew, P. ,  Dang, Qun ,  Hecker, Scott, J. ,  Mali, Venkat, Reddy ,  Chen, Mingwei ,  Sun, Zhili ,  Boyer, Serge, Henri ,  Li, Haiqing ,  Craigo, William

IPC分类号： C07C307/02 ,  C07C309/11 ,  C07C309/15 ,  C07C317/44 ,  C07C323/62 ,  C07D209/20 ,  C07D213/75 ,  C07D261/08 ,  C07D333/38 ,  C07D405/04 ,  C07D498/04 ,  A61K31/185 ,  A61P3/06 ,  A61P3/10

CPC分类号： C07C309/15 ,  C07C307/02 ,  C07C309/11 ,  C07C317/44 ,  C07C323/62 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/74 ,  C07D209/20 ,  C07D213/53 ,  C07D213/75 ,  C07D235/30 ,  C07D261/08 ,  C07D263/56 ,  C07D277/66 ,  C07D307/68 ,  C07D307/81 ,  C07D317/66 ,  C07D333/38 ,  C07D405/04 ,  C07D409/12 ,  C07D413/04 ,  C07D471/04 ,  C07D498/04

摘要： The present invention provides for novel compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as their use in methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistence and hyperglycemia.

摘要翻译： 本发明提供具有胰高血糖素受体拮抗剂或反向激动剂活性的新颖的式I化合物及其药学上可接受的盐和共晶体。 本发明进一步提供包含其的药物组合物以及它们在治疗，预防，延迟发病时间或降低发生或进展一种或多种胰高血糖素受体拮抗剂的疾病或病症的风险的方法中的用途 被指出，包括I型和II型糖尿病，胰岛素抵抗和高血糖。

公开(公告)号：EP2786985A2

公开(公告)日：2014-10-08

申请号：EP14162609.3

申请日：2008-02-11

申请人： Metabasis Therapeutics, Inc.

发明人： Gomez-Galeno, Jorge, E. ,  Reddy, Raja, K. ,  Van Poelje, Paul, D. ,  Lemus, Robert, Huerta ,  Nguyen, Thanh, Huu ,  Grote, Matthew, P. ,  Dang, Qun ,  Hecker, Scott, J. ,  Mali, Venkat, Reddy ,  Chen, Mingwei ,  Sun, Zhili ,  Boyer, Serge, Henri ,  Li, Haiqing ,  Craigo, William

IPC分类号： C07C307/02 ,  C07C309/11 ,  C07C309/15 ,  C07C317/44 ,  C07C323/62 ,  C07D209/20 ,  C07D213/75 ,  C07D261/08 ,  C07D333/38 ,  C07D405/04 ,  C07D498/04 ,  A61K31/185 ,  A61P3/06 ,  A61P3/10

CPC分类号： C07C309/15 ,  C07C307/02 ,  C07C309/11 ,  C07C317/44 ,  C07C323/62 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/74 ,  C07D209/20 ,  C07D213/53 ,  C07D213/75 ,  C07D235/30 ,  C07D261/08 ,  C07D263/56 ,  C07D277/66 ,  C07D307/68 ,  C07D307/81 ,  C07D317/66 ,  C07D333/38 ,  C07D405/04 ,  C07D409/12 ,  C07D413/04 ,  C07D471/04 ,  C07D498/04

摘要： The present invention provides for novel compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as their use in methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistence and hyperglycemia.